Amylyx's ALS treatment Relyvrio fails PhIII study, biotech to consider withdrawing drug

Andrew Dunn

Senior Biopharma Correspondent

Max Gelman

Senior Editor

Relyvrio, Amylyx’s FDA-approved ALS drug, has failed a crucial Phase III trial, the company said on Friday, a major blow to what had been considered …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Amylyx's ALS treatment Relyvrio fails PhIII study, biotech to consider withdrawing drug

Andrew Dunn

Senior Biopharma Correspondent

Max Gelman

Senior Editor

Sign up to read this article for free.

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Are programs with compounded GLP-1s safe for your population?

Amy­lyx's ALS treat­ment Re­lyvrio fails PhI­II study, biotech to con­sid­er with­draw­ing drug

Senior Biopharma Correspondent

Senior Editor

Sign up to read this article for free.

Amylyx's ALS treatment Relyvrio fails PhIII study, biotech to consider withdrawing drug